Navigation Links
QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
Date:9/4/2008

atrophy symptoms of vaginal dryness and dyspareunia.

"We were very pleased with the results of the first Phase 3 trial for Ophena(TM) and believe this next pivotal study will represent another significant development milestone for QuatRx," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "For the large population of postmenopausal women affected by progressive and bothersome vaginal symptoms, and especially those concerned about the health risks associated with long-term estrogen-based therapy, we believe Ophena(TM) has the potential to be an important new treatment option."

About Postmenopausal Vaginal Syndrome

Postmenopausal vaginal syndrome (PVS) is a chronic and progressive condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia) and irritation. Declining estrogen levels during menopause can cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as atrophy. Dryness and irritation associated with reductions in vaginal secretions often cause pain or bleeding during sexual intercourse. It is estimated that 45-75 percent of post-menopausal women experience chronic symptoms of PVS. Current prescription treatments approved for this condition all contain estrogen, administered either orally or locally in the vagina. SERMs that are currently approved and marketed in the United States have not been shown to have beneficial effects on vaginal tissue and none are approved for use in treating symptoms of PVS.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active clinical development and an advanced preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for th
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
2. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
3. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
4. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
5. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
6. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
7. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
8. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
9. Isis Initiates Clinical Trial of CRP Drug
10. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
11. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...27/PRNewswire/--ACUOTECHNOLOGIES,developersofhigh-...ationtoolsandservices,ispleasedtoannouncethattheUn...ntapplicationforan"AssetCommunicationFormatwithina...U.S.patenttoitsportfolioofintellectualproperty.Ing...cuo,stechnologyanduseofassetmetainformationtocontr...
(Date:11/26/2009)...ica,Nov.26/PRNewswire/--The2009Frost&SullivanS...euticalMarketispresentedtoCiplaMedproSouthAfricaLi.../prnh/20081117/FSLOGO ) ,, FortheCompanyoftheYe...laMedpro,sperformanceagainstkeycompetitors:growths...essprocesses,productsand/ortechnologiesandleadersh...
(Date:11/25/2009)...PRNewswire-FirstCall/--AmericanScientificResources...uncethattheyhaveopenedaregionalmarketingandproduct...eenabletosecurealocationabroad,providinganessentia...futurehealthandsafetyproductsforchildrenandadultst...ousesinventoryinthestateofOhiowheretheywillalsobea...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3American Scientific Resources Inc. Opens Shanghai Location 2RNs Praise House Vote to Permit State Single Payer Laws 52009 1RNs Praise House Vote to Permit State Single Payer Laws 52009 2RNs Praise House Vote to Permit State Single Payer Laws 52009 3Five Hypertension Genes Found in Black Americans 52006 1Five Hypertension Genes Found in Black Americans 52006 2Five Hypertension Genes Found in Black Americans 52006 3Omar S Manejwala MD Speaks Out Nationally on Diprivan Propofol Abuse 52002 1Omar S Manejwala MD Speaks Out Nationally on Diprivan Propofol Abuse 52002 2Omar S Manejwala MD Speaks Out Nationally on Diprivan Propofol Abuse 52002 3Omar S Manejwala MD Speaks Out Nationally on Diprivan Propofol Abuse 52002 4
... France, September 1 The ERATO study,published to...r the first,time in patients with permanent atrial...icantly reduces mean 24 hour ventricular rate, on ...ate reduction was 11.7 beats per,minute (p< 0,... is,clinically relevant and highly statistically s...
...alysis of landmark trial showed prasugrel substant...mbosis compared with clopidogrel among ...rmany, Aug. 31 Patients who were,diabetic and dia... percent,less likely to suffer a heart attack if t...ccording to a sub-group analysis of the TRITON-TIM...
Other Medicine Technology:American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation 2American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation 3Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 2Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 3Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 4Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 5
(Date:11/27/2009)...urpose bilingual coloring books designed for child... community to educate - inform parents and childre...s to Dinosuars to ABC,S and a host of other topics...B) November 27, 2009 -- Today’s children hav... busy any hour of the day, but one of the oldest a...
(Date:11/26/2009)...ewswire/--ThediabetespopulationintheUnitedStateswi...endingonthediseaseisprojectedtohit$336billion,upfr...Decemberissueof DiabetesCare .TheNational Changing...,commissionedtheanalysisbyateamfromtheUniversityof...mericanslivingwithdiabeteswillrisefrom23.7millioni...
(Date:11/26/2009)...an emotional rollercoaster, study finds , ...the fear factor meets the jubilant sports fan. ,...ly those who root for the winning team -- enjoy th...d match and victory was in doubt, producing feelin...is Thanksgiving weekend as you,re glued to the TV ...
(Date:11/26/2009)...Communications announces a highly effective and un...struggling to make an economic recovery. , ... fears is the type of challenge that could send ai...g to Dr. David Benton, business growth expert and ...m – The Rfactor Intensive . “Fear i...
(Date:11/25/2009)...PRNewswire-FirstCall/-- OnyxPharmaceuticals,Inc.(...twoinvestoreventsinDecember: ,, ASHBriefing ..., Principalinvestigatorswilldiscussdatapresenta...orymultiplemyeloma,asfeaturedatthe51stAmericanSoci...wOrleans,LA.Theteleconferencewillbeginat9:00a.m.CT...
Breaking Medicine News(10 mins):Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...omplexes which is found to protect cell from trans...al number of chromosomes leading to cell instabili... Van Deursen and his research team from Mayo Clini...n of aneuploidy state. Prof. Deursen has pub...
... University of Toronto stimulates the muscles of p...ease the walking function in those with no hope of...ound that functional electrical stimulation (FES),...their step frequency, stride length and overall wa...
...to be suffering from an acute shortage of nurses, ...e are about 56,000 nurses working across the count...to one nurse for every 950 students, while the fed... Because of this many students who suffer from foo...
...National Laboratories, Gerry Yonas was the first t... border. This led to the development of the Bi...xtends over an area of 4000 square feet at Santa T...or the lab come from USA, State of New Mexico and ...
... his team from Universite de Montreal have found t...ocannabinoids by blocking the degradation in the b...e chemicals present in brain which is responsible ...vel of endocannabinoids is measured by measuring t...
...ersity of Alberta has revealed that a child underg...ealth before its parents divorce. //The study does...he child either. More attention should be paid to ...In the case of children who live in highly dysfunc...
Other Medicine News:Health News:School Children Put To Risk Due To Shortage Of Nurses 2
Streck-CN free Lyse CD Lytic Reagent
... and CVA for CELL-DYN are assayed linearity contro...verify patient reportable range of three- and five...e the linear performance of the analyzer. CVA and ...priate for each instrument model and provide instr...
LATITUDE® Patient Management System
...roprietary EX.P.R.T. Release Technology essentiall..., No stent shortening,, Unique anatomical...rotid bifurcation,, 0.014 Rapid Exchange ca... atraumatic tip,, Radiopaque marker on cath...
Medicine Products: